Rituximab for Leucine-Rich Glioma-Inactivated 1 (LGI1) Antibody-Related Super-refractory Status Epilepticus: A Case Report and Literature Review
Open Access
- 24 March 2025
- journal article
- case report
- Published by Springer Nature in Cureus
- Vol. 17 (3) , e81094
Abstract
Leucine-rich glioma-inactivated 1 (LGI1) encephalitis is a form of autoimmune encephalitis (AE) that presents with memory loss, faciobrachial dystonic seizures (FBDSs), disorientation, psychiatric symptoms, and hyponatremia. Diagnosis is based on clinical presentation, magnetic resonance imaging (MRI), serum or cerebrospinal fluid (CSF) antibody testing, and electroencephalography (EEG) findings. Most available studies on its clinical features and treatment are limited to case reports and series, highlighting the need for a comprehensive understanding and standardized treatment approach. Herein, we report a 61-year-old Saudi retiree with cognitive decline, recurrent right FBDS, generalized tonic-clonic seizures, and persistent hyponatremia who showed a significant improvement after rituximab therapy.Keywords
This publication has 16 references indexed in Scilit:
- Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literatureJournal of Medical Case Reports, 2022
- Role of LGI1 protein in synaptic transmission: From physiology to pathologyNeurobiology of Disease, 2021
- Rituximab Treatment and Long-term Outcome of Patients With Autoimmune EncephalitisNeurology Neuroimmunology & Neuroinflammation, 2021
- Autoimmune encephalitis: clinical spectrum and managementPractical Neurology, 2021
- LGI1 encephalitis associated hyponatremia, is it all in the brain? (2256)Neurology, 2021
- The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesisJournal of Neurology, 2019
- Treatment strategies for autoimmune encephalitisTherapeutic Advances in Neurological Disorders, 2017
- Anti-LGI1 encephalitisNeurology, 2016
- Immune therapy in autoimmune encephalitis: a systematic reviewExpert Review of Neurotherapeutics, 2015
- Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotypeBrain, 2013